Invasive Candidiasis During Granulocytopenia

  • E. Anaissie
  • H. Pinczowski
Part of the Recent Results in Cancer Research book series (RECENTCANCER, volume 132)


Candidiasis remains the most frequently encountered fungal infection in granulocytopenic patients (Horn et al. 1985; Crislip and Edwards 1989). Its increasing frequency has been documented from several institutions and seems highest among patients with acute leukemia. With the advent of newer forms of anticancer therapy, disseminated candidiasis is now more frequently recognized in patients with chronic lymphocytic leukemia receiving fludarabine phosphate and in patients with various malignancies treated with high doses of cytotoxic chemotherapy with autologous bone marrow transplantation.


Chronic Lymphocytic Leukemia Candida Species Invasive Candidiasis Antifungal Prophylaxis Systemic Candidiasis 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Anaissie E, Bodey GP, Kantarjian H (1991) Fluconazole therapy for chronic disseminated candidiasis in patients with leukemia and prior amphotericin B therapy. Am J Med 91: 142–150PubMedCrossRefGoogle Scholar
  2. Bodey GP (1966) Fungal infections complicating acute leukemia. J Chronic Dis 19: 667–687PubMedCrossRefGoogle Scholar
  3. Bodey GP, Luna M (1974) Skin lesions associated with disseminated candidiasis. JAMA 229: 1466–1468PubMedCrossRefGoogle Scholar
  4. Christiansen KJ, Bernard EM, Gold JWM, Armstrong D (1985) Distribution and activity of amphotericin B in humans. J Infect Dis 152: 1037–1043PubMedCrossRefGoogle Scholar
  5. Collette N, Auwera V, Lopez AP, Heymans C, Meunier F (1989) Tissue concentrations and bioactivity of amphotericin B in cancer patients treated with amphotericin B- deoxycholate. Antimicrob Agents Chemother 33: 362–368PubMedGoogle Scholar
  6. Crislip MA, Edwards JE (1989) Candidiasis. Infect Dis Clin North Am 1: 103–133Google Scholar
  7. Dato VM, Dajani AS (1990) Candidemia in children with central venous catheters: role of catheter removal and amphotericin B therapy. J Pediatr Infect Dis 9: 309–314CrossRefGoogle Scholar
  8. EORTC International Antimicrobial Therapy Cooperative Group (1989) Empiric antifungal therapy in febrile granulocytopenic patients. Am J Med 86: 668–672CrossRefGoogle Scholar
  9. Eppes SC, Troutman JL, Gutman LT (1989) Outcome of treatment of candidemia in children whose central catheters were removed or retained. J Pediatr Infect Dis 8: 99–104CrossRefGoogle Scholar
  10. Horn R, Wong B, Kiehn TE, Armstrong D (1985) Fungemia in the immunocompromised host: changing frequency, earlier onset, and results of therapy. Rev Infect Dis 7: 646–655PubMedCrossRefGoogle Scholar
  11. Komshian SV, Uwaydah AK, Sobel JD, Crane LR (1989) Fungemia caused by Candida species and Torulopsis glabrata in the hospitalized patient: frequency, characteristics, and evaluation of factors influencing outcome. Rev Infect Dis 11: 379–390PubMedCrossRefGoogle Scholar
  12. Lecciones J, Witebsky F, Marshall D, Gress J, Pizzo P, Walsh TJ (1989) Catheter-associated fungemia in cancer patients: characteristics and clinical outcome. In: Program and abstracts of the 29th interscience conference on antimicrobial agents and chemotherapy, American Society for Microbiology 112 (abstr 68)Google Scholar
  13. Maksymiuk AW, Thongrasert S, Hopfer R, Luna M, Fainstein V, Bodey GP (1984) Systemic candidiasis in cancer patients. Am J Med 77: 20–27PubMedGoogle Scholar
  14. Pizzo PA, Robichaud KJ, Gill FA, Witebsky FB (1982) Empiric antibiotic and antifungal therapy for cancer patients with prolonged fever and granulocytopenia. Am J Med 72: 101–111PubMedCrossRefGoogle Scholar
  15. Powderly WG, Kobayashi GS, Herzig GP, Medoff G (1988) Amphotericin B resistant yeast infection in severely immunocompromised patients. Am J Med 84: 826–832PubMedCrossRefGoogle Scholar
  16. Rose HD, Kurup VP (1977) Colonization of hospitalized patients with yeast-like organisms. Sabouraudia 15: 251PubMedCrossRefGoogle Scholar
  17. Saag MS, Dismukes WE (1988) Azole antifungal agents: emphasis on new triazoles. Antimicrob Agents Chemother 32: 1–8PubMedGoogle Scholar
  18. Stone HH, Geheber CE, Kolb LD et al. (1973) Alimentary tract colonization by Candida albicans. J Surg Res 14: 273PubMedCrossRefGoogle Scholar
  19. Thaler M, Pastakia B, Shawker TH, O’Leary T, Pizzo PA (1988) Hepatic candidiasis in cancer patients: the evolving picture of the syndrome. Ann Intern Med 108: 88–100PubMedGoogle Scholar

Further Reading

  1. Armstrong D (1989) Problems in the treatment of opportunistic fungal infections. In: Holmberg K, Meyer RD (eds) Armstrong D, pp 149–158 This review analyzes the problems in the diagnosis and treatment of serious mycoses in the immunocompromised host imcluding candidiasis, aspergillosis, mucormycosis, cryptococcosis, the endemic mycoses, and the newly emerging pathogens.Google Scholar
  2. Bodey GP (1986) Infection in cancer patients: a continuing association. Am J Med 81 [Suppl 1A]:11–26 A comprehensive review of infections and host defense defects which complements this chaper.PubMedCrossRefGoogle Scholar
  3. Bodey GP, Fainstein V (1985) Systemic candidiasis. In: Bodey GP, Fainstein V (eds) Bodey GP, Fainstein V, pp 135–168 Summary article on the frequency of, predisposing factors for, clinical signs and symptoms and management of systemic candidiasis.Google Scholar
  4. Goodrich JM, Reed EC, Mori M, Fisher LD, Skerrett S, Dandliker PS, Klis B, Counts GW, Meyers JD (1991) Clinical features and analysis of risk factors for invasive candidal infection after marrow transplantation. J Infect Dis 164:731–740 A review of risk factors for invasive candidiasis among 1506 bone marrow transplant patients at the Fred Hutchinson Cancer Research Center. Tissue involvement was associated with a 90% mortality with or without fungemia. Risk factors for infection were increased age, graft-versus-host disease, and donor mismatch.PubMedCrossRefGoogle Scholar
  5. Klastersky J, Schimpff SC (eds) (1989) International conference on supportive care in oncology. Eur J Cancer Clin Oncol 25:1343–1391 Based on a symposium which emphasized issues related to intensive chemo-therapy of cancer.CrossRefGoogle Scholar
  6. Pizzo PA (1988) Diagnosis and management of infectious disease problems in the child with malignant disease. In: Rubin RH, Young LS (eds) Pizzo PA, pp 439–464 This chapter discusses the appropriate approach for the management of febrile and granulocytopenic patients, including diagnosis and antibiotic treatment.Google Scholar
  7. Schimpff SC, Klastersky J, Gaya H (eds) (1986) Therapy of immunocompromised hosts (symposium). Am J Med 80:1–119 A broad-based series covering basic and clinical concerns in therapy with emphasis on granulocytopenic patients and current controversies such as combination versus monotherapy.Google Scholar
  8. Wade JC, Schimpff SC (1985) Epidemiology and prevention of Candida infection. In: Bodey GP, Fainstein V (eds) Wade JC, Schimpff SC, pp 111 – 133 This chapter discusses the various aspects of the pathogenesis, mechanisms of infection, protal of invasion, and prevention of candidal infections.Google Scholar
  9. Walsh TJ, Pizzo PA (1988) Treatment of systemic fungal infections: recent progress and current problems. Eur J Clin Microbiol 7:460–475 This review summarizes the current problems in diagnosing fungal infections and the emergence of newer fungi as serious pathogens and discusses antifungal chemotherapy with special emphasis on specific therapy of the various mycoses.CrossRefGoogle Scholar
  10. Zinner SH, Klastersky J (1985) Infectious considerations in cancer. In: Calabresi P, Schein PS, Rosenberg SA (eds) Medical oncology: basic principles and clinical management of cancer. Macmillan, New York, pp 1327–1357Google Scholar

Copyright information

© Springer-Verlag Berlin · Heidelberg 1993

Authors and Affiliations

  • E. Anaissie
    • 1
  • H. Pinczowski
    • 1
  1. 1.The University of Texas M. D. Anderson Cancer CenterTexas Medical CenterHoustonUSA

Personalised recommendations